Drug General Information (ID: DDIJ6GM50C)
Drug Name			Rasagiline		Drug Info		Vilanterol		Drug Info
Drug Type		Small molecule				Small molecule
Therapeutic Class		Antiparkinson Agents				Bronchodilators
Structure

Mechanism of Rasagiline-Vilanterol Interaction (Severity Level: Moderate)
Additive hypertensive effects Click to Show/Hide Mechanism Graph
Drug Name		Rasagiline				Vilanterol
Mechanism		Hypertensive effects				Hypertensive effects
Key Mechanism Factor 1
		Factor Name		Hypertensive effects
		Factor Description		Hypertension is defined as a blood pressure reading above a prescribed limit (130/90 mmHg). Most people with hypertension have no signs or symptoms; others may experience: severe headache, shortness of breath, nosebleeds, severe anxiety, and feeling a tingling sensation in the neck or head.
Mechanism Description		Additive hypertensive effects by the combination of Rasagiline and Vilanterol

Recommended Action
Management		Cardiovascular status should be closely monitored when beta-2 agonists are coadministered with MAOIs or other agents that possess MAOI activity (e.g., furazolidone, linezolid, methylene blue, procarbazine). Preferably, at least 14 days should elapse between discontinuation of MAOI therapy and initiation of treatment with beta-2 agonists.

References
1	Boakes AJ, Laurence DR, Teoh PC, Barar FS, Benedikter LT, Prichard BN "Interactions between sympathomimetic amines and antidepressant agents in man." Br Med J 1 (1973): 311-5. [PMID: 4685619]
2	Product Information. Brovana (arformoterol). Sepracor Inc, Marlborough, MA.
3	Product Information. Xopenex (levalbuterol). Sepracor, Marlborough, MA.